Skip to main
  1. Stocks
  2. RenovoRx
  3. Forecast
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx is attractive fundamentally because its FDA-cleared RenovoCath device is showing rapid commercial traction, with active cancer centers rising from about 12 at the beginning of 2026 to 26 currently, supporting a revenue increase to $1.1 million in fiscal Q3 2026, up 301% year over year. Its TAMP platform and lead RenovoGem program add longer-term upside, since the Phase 3 TIGeR-PaC trial has progressed through a positive second interim review, completed enrollment in August 2026, and remains on track for completion in 1H 2027 with top-line data expected in 2H 2027. The balance sheet also looks manageable with $10 million in cash and no debt, while the cited ~billion dollars market potential and projected 2026/27 revenue growth reinforce the view that the shares are undervalued relative to the opportunity.

Bears say

RenovoRx is a clinical-stage biopharmaceutical company with no established commercial product, leaving its valuation heavily dependent on future trial outcomes and regulatory success rather than recurring revenue. Its prospects are constrained by balance sheet and liquidity risk, and the company still faces significant uncertainty around demonstrating safety and efficacy, securing approvals, and proving it can commercialize its targeted delivery platform. Even if the technology shows promise, reimbursement hurdles, competition, macroeconomic pressure, and weak biotech investor sentiment could limit adoption and financing flexibility, reinforcing a negative fundamental outlook.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

RenovoRx (RNXT) Analyst Forecast & Price Prediction

Get the latest RenovoRx (RNXT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RenovoRx (RNXT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


RenovoRx (RNXT) Analyst Forecast & Price Prediction

Get the latest RenovoRx (RNXT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RenovoRx (RNXT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RNXT stock data and trends